Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis and Septic Shock | CMAC

Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis and Septic Shock

Clinical Microbiology and Antimicrobial Chemotherapy. 2005; 7(3):208-234

​ Dellinger R.P., Carler J.M., Masur H., Gerlach H., Calandra T., Cohen J., Gea-Banacloche J., Keh D., Marshall J.C., Parker M.M., Ramsay G., Zimmerman J.L., Vincent J.-L., Levy M.M., for the Surviving Sepsis Campaign Management Guidelines Committee
sepsis severe sepsis septic shock sepsis syndrome infection guidelines evidence-based medicine Surviving Sepsis Campaign
Section
Guidelines
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2005; 7(3):208-234

Abstract

Reproduced with permission from the Society of Critical Care Medicine, the European Society of Intensive Care and Medicine and the International Sepsis Forum.

Objective.

In 2003, critical care and infectious disease experts representing 11 international organizations developed management guidelines for severe sepsis and septic shock that would be of practical use for the bedside clinician, under the auspices of the Surviving Sepsis Campaign, an international effort to increase awareness and improve outcome in severe sepsis.

Design.

The process included a modified Delphi method, a consensus conference, several subsequent smaller meetings of subgroups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee.

Materials and Methods.

We used a modified Delphi methodology for grading recommendations, built on a 2001 publication sponsored by the International Sepsis Forum. We undertook a systematic review of the literature graded along five levels to create recommendation grades from A to E, with A being the highest grade. Pediatric considerations were provided to contrast adult and pediatric management.

Results.

Key recommendations, listed by category and not by hierarchy, include early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition; appropriate diagnostic studies to ascertain causative organisms before starting antibiotics; early administration of broad-spectrum antibiotic therapy; reassessment of antibiotic therapy with microbiology and clinical data to narrow coverage, when appropriate; a usual 7–10 days of antibiotic therapy guided by clinical response; source control with attention to the method that balances risks and benefits; equivalence of crystalloid and colloid resuscitation; aggressive fluid challenge to restore mean circulating filling pressure; vasopressor preference for norepinephrine and dopamine; cautious use of vasopressin pending further studies; avoiding low-dose dopamine administration for renal protection; consideration of dobutamine inotropic therapy in some clinical situations; avoidance of supranormal oxygen delivery as a goal of therapy; stress-dose steroid therapy for septic shock; use of recombinant activated protein C in patients with severe sepsis and high risk for death; with resolution of tissue hypoperfusion and in the absence of coronary artery disease or acute hemorrhage, targeting a hemoglobin of 7–9 g/dL; appropriate use of fresh frozen plasma and platelets; a low tidal volume and limitation of inspiratory plateau pressure strategy for acute lung injury and acute respiratory distress syndrome; application of a minimal amount of positive end-expiratory pressure in acute lung injury/acute respiratory distress syndrome; a semirecumbent bed position unless contraindicated; protocols for weaning and sedation/analgesia, using either intermittent bolus sedation or continuous infusion sedation with daily interruptions/lightening; avoidance of neuromuscular blockers, if at all possible; maintenance of blood glucose <150 mg/dL after initial stabilization; equivalence of continuous veno-veno hemofiltration and intermittent hemodialysis; lack of utility of bicarbonate use for pH >7.15; use of deep vein thrombosis/stress ulcer prophylaxis; and consideration of limitation of support where appropriate. Pediatric considerations included a more likely need for intubation due to low functional residual capacity; more difficult intravenous access; fluid resuscitation based on weight with 40–60 mL/kg or higher needed; decreased cardiac output and increased systemic vascular resistance as the most common hemodynamic profile; greater use of physical examination therapeutic end points; unsettled issue of high-dose steroids for therapy of septic shock; and greater risk of hypoglycemia with aggressive glucose control.

Conclusions.

Evidence-based recommendations can be made regarding many aspects of the acute management of sepsis and septic shock that are hoped to translate into improved outcomes for the critically ill patient. The impact of these guidelines will be formally tested and guidelines updated annually and even more rapidly as some important new knowledge becomes available.

  • 1. Dellinger R.P. Cardiovascular management of septic shock. Crit Care Med 2003; 31:946-55.
  • 2. Friedman G., Silva E., Vincent J.L. Has the mortality of septic shock changed with time? Crit Care Med 1998; 26:2078-86.
  • 3. Sackett D.L. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1989; 95:2S-4S.
  • 4. Sprung C.L., Bernard G.R., Dellinger R.P. Introduction. Intensive Care Med 2001; 27(Suppl):S1-S2.
  • 5. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-77.
  • 6. Weinstein M.P., Reller L.P., Murphy J.R., et al. The clinical significance of positive blood cultures: A comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. Rev Infect Dis 1983; 5:35-53.
  • 7. Blot F., Schmidt E., Nitenberg G., et al. Earlier positivity of central venous versus peripheral blood cultures is highly predictive of catheter-related sepsis. J Clin Microbiol 1998; 36:105-9.
  • 8. Mermel L.A., Maki D.G. Detection of bacteremia in adults: Consequences of culturing an inadequate volume of blood. Ann Intern Med 1993; 119:270-2.
  • 9. McCabe W.R., Jackson G.G. Gram negative bacteremia. Arch Intern Med 1962; 110:92-100.
  • 10. Kreger B.E., Craven D.E., McCabe W.R. Gram negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 1980; 68:344-55.
  • 11. Leibovici L., Shraga I., Drucker M., et al. The benefit of appropriate empirical antibiotic treatment in pa ti ents with bloodstream infection. J Intern Med 1998; 244:379-86.
  • 12. Ibrahim E.H., Sherman G., Ward S., et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-55.
  • 13. Hatala R., Dinh T., Cook D.J. Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis. Ann Intern Med 1996; 124:717-25.
  • 14. Ali M.Z., Goetz M.B. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24:796-809.
  • 15. Amsden G.W., Ballow C.H., Bertino J.S. Pharmacokinetics and pharmacodynamcis of anti-infective agents. In: Principles and Practice of Infectious Diseases. 5th ed. Mandell G.L., Bennett J.E., Dolin R., editors. Philadelphia: Churchill Livingstone; 2000. pp. 253-261.
  • 16. Hyatt J.M., McKinnon P.S., Zimmer G.S., et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcomes. Focus on antibacterial agents. Clin Pharmacokinet 1995; 28:143-60.
  • 17. Jimenez M.F., Marshall J.C. Source control in the management of sepsis. Intensive Care Med 2001; 27:S49-S62.
  • 18. Bufalari A., Giustozzi G., Moggi L. Postoperative intraabdominal abscesses: percutaneous versus surgical treatment. Acta Chir Belg 1996; 96:197-200.
  • 19. Moss R.L., Musemeche C.A., Kosloske A.M. Necrotizing fas citis in children: prompt recognition and aggressive therapy improve survival. J Pediatr Surg 1996; 31:1142-6.
  • 20. Centers for Disease Control and Prevention. Guidelines for the Prevention of Intravascular Catheter-Related Infections. MMWR 2002; 51:1-29.
  • 21. O’Grady N.P., Alexander M., Dellinger E.P., et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2002; 35:1281-307.
  • 22. Choi P.T.L., Yip G., Quinonez L.G., et al. Crystalloids vs. colloids in fluid resuscitation: a systematic review. Crit Care Med 1999; 27:200-10.
  • 23. Cook D., Guyatt G. Colloid use for fluid resuscitation: evidence and spin. Ann Intern Med 2001; 135:205-8.
  • 24. Schierhout G., Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomized trials. BMJ 1998; 316:961-4.
  • 25. Hollenberg S.M., Ahrens T.S., Astiz M.E., et al. Practice parameters for hemodynamic support of sepsis in adult patients. Crit Care Med 1999; 27:639-60.
  • 26. LeDoux D., Astiz M.E., Carpati C.M., et al. Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med 2000; 28:2729-32.
  • 27. Regnier B., Rapin M., Gory G., et al. Haemodynamic effects of dopamine in septic shock. Intensive Care Med 1977; 3:47-53.
  • 28. Martin C., Papazian L., Perrin G., et al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993; 103:1826-31.
  • 29. Martin C., Viviand X., Leone M., et al. Effect of norepinephrine on the outcome of septic shock. Crit Care Med 2000; 28:2758-65.
  • 30. De Backer D., Creteur J., Silva E., et al. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med 2003; 31:1659-67.
  • 31. Bellomo R., Chapman M., Finfer S., et al. Low-dose dopamine in patients with early renal dysfunction: A placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356:2139-43.
  • 32. Kellum J., Decker J. Use of dopamine in acute renal failure: A meta-analysis. Crit Care Med 2001; 29:1526-31.
  • 33. Sharshar T., Blanchard A., Paillard M., et al. Circulating vasopressin levels in septic shock. Crit Care Med 2003; 31:1752-58.
  • 34. Holmes C.L., Patel B.M., Russell J.A., et al. Physiology of vasopressin relevant to management of septic shock. Chest 2001; 120:989-1002.
  • 35. Malay M.B., Ashton R.C., Landry D.W., et al. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999; 47:699-705.
  • 36. Holmes C.L., Walley K.R., Chittock D.R., et al. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 2001; 27:1416-21.
  • 37. Gattinoni L., Brazzi L., Pelosi P., et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 1995; 333:1025-32.
  • 38. Hayes M.A., Timmins A.C., Yau E.H.S., et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330:1717-22.
  • 39. Annane D., Sebille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-71.
  • 40. Briegel J., Forst H., Haller M., et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27:723-32.
  • 41. Bollaert P.E., Charpentier C., Levy B., et al. Reversal of ate septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26:645-50.
  • 42. Annane D., Sebille V., Troche G., et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000; 283:1038-45.
  • 43. Annane D., Cavaillon J.M. Corticosteroids in sepsis: from bench to bedside? Shock 2003; 20:197-207.
  • 44. Marik P.E., Zaloga G.P. Adrenal insufficiency during septic shock. Crit Care Med 2003; 31:141-5.
  • 45. Cooper M.S., Stewart P.M. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348:727-34.
  • 46. Keh D., Boehnke T., Weber-Carstens S., et al. Immunologic and hemodynamic effects of «low-dose» hydrocortisone in septic shock: a double-blind, randomized, placebocontrolled, crossover study. Am J Respir Crit Care Med 2003; 167:512-20.
  • 47. Bone R.C., Fisher C.J., Clemmer T.P. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653-8.
  • 48. Cronin L., Cook D.J., Carlet J., et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23:1430-9.
  • 49. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect on high-dose glucocorticoid thera py on mortality in patients with clinical signs of sepsis. N Engl J Med 1987; 317:659-65.
  • 50. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
  • 51. Hébert P.C., Wells G., Blajchman M.A., et al. A multicenter, randomized, controlled clinical trial of transfusion in critical care. N Engl J Med 1999; 340:409-17.
  • 52. Marik P.E., Sibbald W.J. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA 1993; 269:3024-9.
  • 53. Lorente J.A., Landín L., De Pablo R., et al. Effects of blood transfusion on oxygen transport variables in severe sepsis. Crit Care Med 1993; 21:1312-8.
  • 54. Corwin H.L., Gettinger A., Rodriguez R.M., et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized double-blind, placebo-controlled trial. Crit Care Med 1999; 27:2346-50.
  • 55. Corwin H.L., Gettinger A., Pearl R.G., et al. Efficacy of recombinant human erythropoietin in critically ill patients. JAMA 2002; 288:2827-35.
  • 56. Practice parameter for the use of freshfrozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists. JAMA 1994; 271:777-81.
  • 57. Guidelines for red blood cell and plasma transfusion for adults and children. Report of the Working Group. CMAJ 1997; 156 (Suppl):S1-S24.
  • 58. Practice guidelines for blood component therapy. A report by the American Society of Anaesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996; 84:732-47.
  • 59. Warren B.L., Eid A., Singer P., et al. High-dose antithrombin III in severe sepsis. A randomized controlled trial. JAMA 2001; 286:1869-78.
  • 60. Amato M.B., Barbas C.S., Medeiros D.M., et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998; 338:347-54.
  • 61. Stewart T.E., Meade M.O., Cook D.J., et al. Evaluation of a ventilation strategy to prevent barotrauma in patients at high risk for acute respiratory distress syndrome. Pressure- and Volume-Limited Ventilation Strategy Group. N Engl J Med 1998; 338:355-61.
  • 62. Brochard L., Roudat-Thoraval F., Roupie E., et al. Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome. The Multicenter Trial Group on Tidal Volume reduction in ARDS. Am J Respir Crit Care Med 1998; 158:1831-8.
  • 63. Brower R.G., Shanholtz C.B., Fessler H.E., et al. Prospective, randomized, controlled clinical trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients. Crit Care Med 1999; 27:1492-8.
  • 64. Brower R.G., Fessler H.E. Mechanical ventilation in acute lung injury and acute respiratory distress syndrome. Clin Chest Med 2000; 21:491-510.
  • 65. Eichacker P.Q., Gerstenberger E.P., Banks S.M., et al. Meta-analysis of acute lung injury and acute respiratory distress syndrome trials testing low tidal volumes. Am J Respir Crit Care Med 2002; 166:1510-4.
  • 66. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342:1301-8.
  • 67. Hickling K.G., Walsh J., Henderson S., et al. Low mortality rate in adult respiratory distress syndrome using low-volume, pressure-limited ventilation with permissive hypercapnia: a prospective study. Crit Care Med 1994; 22:1568-78.
  • 68. Bidani A., Tzouanakis A.E., Cardenas V.J., et al. Permissive hypercapnia in acute respiratory failure. JAMA 272:957-62.
  • 69. Marini J.J., Ravenscraft S.A. Mean airway pressure: physiologic determinants and clinical importance. Part I. Physiologic determinants and measurements. Crit Care Med 1992; 20:1461-72.
  • 70. Gattinoni L., Marcolin R., Caspani M.L., et al. Constant mean airway pressure with different patterns of positive pressure breathing during the adult respiratory distress syndrome. Bull Eur Physiopathol Respir 1985; 21:275-9.
  • 71. Pesenti A., Marcolin R., Prato P., et al. Mean airway pressure vs. positive end-expiratory pressure during mechanical ventilation. Crit Care Med 1985; 13:34-7.
  • 72. Stocker R., Neff T., Stein S., et al. Prone positioning and low-volume pressurelimited ventilation improve survival in patients with severe ARDS. Chest 1997; 111:1008-17.
  • 73. Lamm W.J., Graham M.M., Albert R.K. Mechanism by which prone position improves oxygenation in acute lung injury. Am J Respir Crit Care Med 1994; 150:184-93.
  • 74. Jolliet P., Bulpa P., Chevrolet J.C. Effects of the prone po si ti on on gas exchange and hemodynamics in severe acute respiratory distress syndrome. Crit Care Med 1998; 26:1977-85.
  • 75. Gattinoni L., Tognoni G., Pesenti A., et al. Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med 2001; 345:568-73.
  • 76. Chatte G., Sab J.M., Dubois J.M., et al. Prone position in mechanically ventilated patients with severe acute respiratory failure. Am J Respir Crit Care Med 1997; 155:473-8.
  • 77. Drakulovic M., Torres A., Bauer T., et al. Supine body posi tion as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. Lancet 1999; 354:1851-8.
  • 78. Esteban A., Alia I., Tobin M.J., et al. Effect of spontaneous breathing trial duration on outcome of attempts to discontinue mechanical ventilation. Spanish Lung Failure Collaborative Group. Am J Respir Crit Care Med 1999; 159:512-8.
  • 79. Ely E.W., Baker A.M., Dunagan D.P., et al. Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. N Engl J Med 1996; 335:1864-9.
  • 80. Esteban A., Alia I., Gordo F., et al. Extubation outcome after spontaneous breathing trials with T-tube or pressure support ventilation. The Spanish Lung Failure Colla borative Group. Am J Respir Crit Care Med 1997; 156:459-65.
  • 81. Kollef M.H., Levy N.T., Ahrens T.S., et al. The use of continuous IV sedation is associated with prolongation of mechanical ventilation. Chest 1998; 114:541-8.
  • 82. Kress J.P., Pohlman A.S., O’Connor M.F., et al. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000; 342:1471-7.
  • 83. Brook A.D., Ahrens T.S., Schaiff R., et al. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med 1999; 27:2609-15.
  • 84. Giostra E., Magistris M.R., Pizzolato G., et al. Neuromuscular disorder in intensive care unit patients treated with pancuronium bromide. Occurrence in a cluster group of seven patients and two sporadic cases, with electrophysiologic and histologic examination. Chest 1994; 106:210-20.
  • 85. Rossiter A., Souney P.F., McGowan S., et al. Pancuronium-induced prolonged neuromuscular blockade. Crit Care Med 1991; 19:1583-7.
  • 86. Partridge B.L., Abrams J.H., Bazemore C., et al. Prolonged neuromuscular blockade after long-term infusion of vecuronium bromide in the intensive care unit. Crit Care Med 1990; 18:1177-9.
  • 87. Vanderheyden B.A., Reynolds H.N., Gerold K.B., et al. Prolonged paralysis after longterm vecuronium infusion. Crit Care Med 1992; 20:304-7.
  • 88. Meyer K.C., Prielipp R.C., Grossman J.E., et al. Prolonged weakness after infusion of atracurium in two intensive care unit patients. Anesth Analg 1994; 78:772-4.
  • 89. Manthous C.A., Chatila W. Prolonged weakness after withdrawal of atracurium. Am J Respir Crit Care Med 1994; 150:1441-3.
  • 90. Prielipp R.C., Coursin D.B., Scuderi P.E., et al. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients. Anesth Analg 1995; 81:3-12.
  • 91. Brandom B.W., Yellon F.F., Lloyd M.E., et al. Recovery from doxacurium infusion administered to produce immobility for more than four days in pediatric patients in the intensive care unit. Anesth Analg 1997; 84:307-14.
  • 92. Rudis M.I., Sikora C.A., Angus E., et al. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med 1997; 25:25575-83.
  • 93. Frankel H., Jeng J., Tilly E., et al. The impact of implementation of neuromuscular blockade monitoring standards in a surgical intensive care unit. Am Surg 1996; 62:503-6.
  • 94. Van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345:1359-67.
  • 95. Finney S.J., Zekveld C., Elia A., et al. Glucose control and mortality in critically ill patients. JAMA 2003; 2041-7.
  • 96. Van den Berghe G., Wouters P.J., Bouillon R., et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 2003; 31:359-66.
  • 97. Klein S., Kinney J., Jeejeebhoy K., et al. Nutrition support in clinical practice: review of published data and recommendations for future research directions. A summary of a conference sponsored by the National Institutes of Health, American Society for Parenteral and Enteral Nutrition, and American Society for Clinical Nutrition. Am J Clin Nutr 1997; 66:683-706.
  • 98. Mehta R.L., McDonald B., Gabbai F.B., et al. A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. Kidney Int 2001; 60:1154-63.
  • 99. Kellum J., Angus D.C., Johnson J.P., et al. Continuous versus intermittent renal replacement therapy: a meta-analysis. Intensive Care Med 2002; 28:29-37.
  • 100. Cooper D.J., Walley K.R., Wiggs B.R., et al. Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis: a prospective, controlled clinical study. Ann Intern Med 1990; 112:492-8.
  • 101. Mathieu D., Neviere R., Billard V., et al. Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis: a prospective, controlled clinical study. Crit Care Med 1991; 19:1352-6.
  • 102. Cade J.F. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982; 10:448-50.
  • 103. Belch J.J., Lowe G.D., Ward A.G., et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981; 26:115-7.
  • 104. Samama M.M., Cohen A.T., Darmon J.Y., et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341:793-800.
  • 105. Borrero E., Bank S., Margolis I., et al. Comparison of antacid and sucralfate in the prevention of gastrointestinal bleeding in patients who are critically ill. Am J Med 1985; 79:62-4.
  • 106. Bresalier R.S., Grendell J.H., Cello J.P., et al. Sucralfate versus titrated antacid for the prevention of acute stress-related gastrointestinal hemorrhage in critically ill patients. Am J Med 1987; 83:110-6.
  • 107. Cook D., Guyatt G., Marshall J., et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med 1998; 338:791-7.
  • 108. Stothert J.C., Simonowitz D.A., Dellinger E.P., et al. Randomized prospective evaluation of cimetidine and antacid control of gastric pH in the critically ill. Ann Surg 1980; 192:169-74.
  • 109. Pollard A.J., Britto J., Nadel S., et al. Emergency management of meningococcal disease. Arch Dis Child 1999; 80:290-6.
  • 110. Kanter R.K., Zimmerman J.J., Strauss R.H., et al. Pediatric emergency intravenous access. Evaluation of a protocol. Am J Dis Child 1986; 140:132-4.
  • 111. Ngo N.T., Cao X.T., Kneen R., et al. Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour. Clin Infect Dis 2001; 32:204-13.
  • 112. Carcillo J.A., Davis A.L., Zaritsky A. Role of early fluid resuscitation in pediatric septic shock. JAMA 1991; 266:1242-5.
  • 113. Powell K.R., Sugarman L.I., Eskenazi A.E., et al. Normalization of plasma arginine vasopressin concentrations when children with meningitis are given maintenance plus replacement fluid therapy. J Pediatr 1991; 117:515-22.
  • 114. Ceneviva G., Paschall J.A., Maffei F., et al. Hemodynamic support in fluid-refractory pediatric septic shock. Pediatrics 1998; 102:e19.
  • 115. Keeley S.R., Bohn D.J. The use of inotropic and afterload-reducing agents in neonates. Clin Perinatol 1988; 15:467-89.
  • 116. Roberts J.D. Jr., Fineman J.R., Morin F.C. III., et al. Inhaled nitric oxide and persistent pulmonary hypertension of the new born. Inhaled Nitric Oxide Study Group. N Engl J Med 1997; 336:605-10.
  • 117. Barton P., Garcia J., Kouatli A., et al. Hemodynamic effects of i. v. milrinone lactate in pediatric patients with septic shock. A prospective, double-blinded, randomized, placebo-controlled, interventional study. Chest 1996; 109:1302-12.
  • 118. Lindsay C.A., Barton P., Lawless S., et al. Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. J Pediatr 1998; 132:329-34.
  • 119. Irazuzta J.E., Pretzlaff R.K., Rowin M.E. Amrinone in pediatric refractory septic shock: an open-label pharmacodynamic study. Pediatr Crit Care Med 2001; 2:24-8.
  • 120. Lauterbach R., Pawlik D., Kowalczyk D., et al. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebocontrolled, double-blind trial. Crit Care Med 1999; 27:807-14.
  • 121. Carcillo J.A., Fields A.I., American College of Critical Care Medicine Task Force Committee Members. Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit Care Med 2002; 30:1365-78.
  • 122. De Kleijn E.D., Joosten K.F., Van Rijn B., et al. Low serum cortisol in combination with high adrenocorticotrophic hormone concentrations are associated with poor outcome in children with severe meningococcal disease. Pediatr Infect Dis J 2002; 21:330-6.
  • 123. Riordan F.A., Thomson A.P., Ratcliffe J.M., et al. Admission cortisol and adrenocorticotrophic hormone levels in children with meningococcal disease: evidence of adrenal insufficiency? Crit Care Med 1999; 27:2257-61.
  • 124. Min M., U T., Aye M., et al. Hydrocortisone in the management of dengue shock syndrome. Southeast Asian J Trop Med Public Health 1975; 6:573-9.
  • 125. Sumarmo, Talogo W., Asrin A., et al. Failure of hydrocortisone to affect outcome in dengue shock syndrome. Pediatrics 1982; 69:45-9.
  • 126. Hazelzet J.A., de Kleijn E.D., de Groot R. Endothelial protein C activation in meningococcal sepsis. N Engl J Med 2001; 345:1776-7.
  • 127. de Kleijn E.D., de Groot R., Hack C.E., et al. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 2003; 31:1839-47.
  • 128. Bilgin K., Yaramis A., Haspolat K., et al. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics 2001; 107:36-41.
  • 129. La Gamma E.F., De Castro M.H. What is the rationale for the use of granulocyte and granulocyte-macrophage colonystimulating factors in the neonatal intensive care unit? Acta Paediatr Suppl 2002; 91:109-16.
  • 130. Chaïbou M., Tucci M., Dugas M.A., et al. Clinically bou M., Tucci M., Dugas M.A., et al. Clinically significant upper gastrointestinal bleeding acquired in a pediatric intensive care unit: a prospective study. Pediatrics 1998; 102:933-8.
  • 131. Gauvin F., Dugas M., Chaïbou M., et al. The impact of bou M., et al. The impact of clinically significant upper gastrointestinal bleeding in a pediatric intensive care unit. Pediatr Crit Care Med 2001; 2:294-8.
  • 132. Alejandria M.M., Lansang M.A., Dans L.F., et al. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2002; (1): CD001090.
  • 133. Meyer D.M., Jessen M.E. Results of extracorporeal membrane oxygenation in children with sepsis. The Extracorporeal LifeSupport Organization. Ann Thorac Surg 1997; 63:756-61.
  • 134. Goldman A.P., Kerr S.J., Butt W., et al. Extracorporeal support for intractable cardiorespiratory failure due to meningococcal disease. Lancet 1997; 349:466-9.
  • 135. Brochard L., Rauss A., Benito S., et al. Comparison of three methods of gradual withdrawal from ventilatory support during weaning from mechanical ventilation. Am J Respir Crit Care Med 1994; 150:896-903.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared